-Application No.: 10/084,380 - 5 - Docket No.: 20555/0203244-US0

AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior claims presented in the application.

- 1-13. (Canceled)
- 14. (Currently amended) A method for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof in the brain, comprising the step of administering to a subject in need of such inhibition an antibody which is targeted to an amyloid β peptide, or to fragment thereof, thereby delaying or inhibiting or suppressing accumulation of said amyloid β peptide or fragment thereof in the brain of said subject.
 - 15. (Canceled)
- 16. (Original) The method of claim 14, wherein the antibody is directed to N-terminus-truncated amyloid β peptide fragment.
- 17. (Original) The method of claim 14, wherein the antibody is directed to C-terminus-truncated amyloid β peptide fragment.
- 18. (Original) The method of claim 14, wherein the antibody is directed to the amyloid precursor protein, or fragment thereof.
- 19. (Original) The method of claim 14, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.
- 20. (Currently amended) A method for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering to a subject in need of such inhibition an antibody which is targeted to amyloid β peptide, or fragment thereof, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof in said subject.
 - 21. (Canceled)
- 22. (Original) The method of claim 20, wherein the antibody is directed to N-terminus-truncated amyloid β peptide fragment.
- 23. (Original) The method of claim 20, wherein the antibody is directed to C-terminus-truncated amyloid β peptide fragment.

Docket No.: 20555/0203244-US0

Application No.: 10/084,380

- 6 -

- · 24. (Original) The method of claim 20, wherein the antibody is directed to the amyloid precursor protein, or fragment thereof.
- 25. (Original) The method of claim 20, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

26-50. (Canceled)

- 51. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and targeted to the free N-terminus of amyloid β-peptide or a fragment thereof for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 26, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.
- 52. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and targeted to the free N-terminus of amyloid β-peptide or a fragment thereof for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 26, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

53-54. (Canceled)

- 55. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and is targeted to the free N-terminus of amyloid β -peptide or a fragment thereof, wherein the first amino acid of said N-terminus is aspartate for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 28, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.
- 56. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and is targeted to the free N-terminus of amyloid β -peptide or a fragment thereof, wherein the first amino acid of said N-terminus is aspartate for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 28, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

57-58. (Canceled)

Application No.: 10/084,380 - 7 - Docket No.: 20555/0203244-US0

59. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and targeted to a free N-terminus of an amyloid β peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 30, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

60. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and targeted to a free N-terminus of an amyloid β peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 30, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

61-62. (Canceled)

- 63. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and targeted to the free C-terminus of the amyloid β -peptide A β 1-39, A β 1-40, A β 1-41, or A β 1-43 for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 32, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.
- 64. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and targeted to the free C-terminus of the amyloid β -peptide A β 1-39, A β 1-40, A β 1-41, or A β 1-43 for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 32, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.

65-66. (Cancelled)

67. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and targeted to a free C-terminus of an amyloid β peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the

Application No.: 10/084,380 - 8 - Docket No.: 20555/0203244-US0

antibody of claim 34, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.

- 68. (Currently Amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and targeted to a free C-terminus of an amyloid β peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 34, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.
 - 70. (Canceled)
- 71. (Currently amended) [[A]] The method of claim 14, wherein the antibody is free-end specific and is targeted to the free C-terminus of the amyloid β- peptide Aβ1-42 for delaying or inhibiting or suppressing the accumulation of an amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 36, thereby delaying or inhibiting or suppressing accumulation of amyloid β peptide or fragment thereof in the brain.
- 72. (Currently amended) [[A]] The method of claim 20, wherein the antibody is free-end specific and is targeted to the free C-terminus of the amyloid β peptide A β 1-42 for delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof, comprising the step of administering the antibody of claim 36, thereby delaying or inhibiting or suppressing the neurotoxicity of amyloid β peptide or fragment thereof.